PF-4708671
目录号 : GC10689
PF-4708671 是一种新型的细胞渗透性 S6K1 抑制剂，特异性抑制 S6K1 亚型，Ki 为 20 nM，IC50 为 160 nM。
Cas No.:1255517-76-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PF-4708671, is a novel cell-permeable inhibitor of S6K1, specifically inhibits the S6K1 isoform with a Ki of 20 nM and IC50 of 160 nM. [1].
PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), PF-4708671 was also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1) [1]. RSK1, RSK2 and MSK1 were the other kinases inhibited by PF-4708671 (IC50 = 4.7 μM, 9.2 μM and 0.95 μM, respectively). PF-4708671 decreased phosphorylation of ribosomal protein S6 in HEK-293 cells. PF-4708671 has been used as the standard S6K1 inhibitor for the investigation of the role of S6K1 in several cancers. PF-4708671 in combination with tamoxifen was shown to be highly effective against ER+ MCF7 cells that had overexpression of S6K1 [2] and enhanced cell death in glucose-starved MCF7 cells via downregulation of anti-apoptotic proteins Mcl-1 and survivin [3].
PF-4708671 inhibite the AKT/mTOR/S6K1 pathway led to the inhibition of cell migration in triple-negative MDA-MB-231 cells and inhibition of local relapse in mice models [4]. Moreover, PF-4708671 improved glucose tolerance in high-fat -fed obese mice by restoring Akt S473 phosphorylation in metabolic tissues [5]. PF-4708671 has protective effects against NMDA-induced retinal neurotoxicity in rats [6].
References:
[1]. Pearce, L. R. et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245-255 (2010).
[2]. Hong SE, Kim EK, Jin HO, Kim HA, Lee JK, Koh JS, et al. S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. Cell Biol Toxicol. 2013;29(4):273-82.
[3]. Choi HN, Jin HO, Kim JH, Hong SE, Kim HA, Kim EK, et al. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2013;432(1):123-8.
[4]. Segatto I, Berton S, Sonego M, Massarut S, D'Andrea S, Perin T, et al. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol. 2013;5(6):428-31.
[5]. M. Shum, K. Bellmann, P. St-Pierre, A. Marette. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice .Diabetologia, 59 (2016), pp. 592-603
[6]. Hayashi, I.; Aoki, Y.; Ushikubo, H.; Asano, D.; Mori, A.; Sakamoto, K.; Nakahara, T.; Ishii, K. Protective effects of PF-4708671 againstN-methyl-d-aspartic acid-induced retinal damage in rats. Fundam. Clin. Pharmacol. 2016, 30, 529-536.
PF-4708671 是一种新型的细胞渗透性 S6K1 抑制剂，特异性抑制 S6K1 亚型，Ki 为 20 nM，IC50 为 160 nM。 [1].
PF-4708671 阻止 S6K1 介导的 S6 蛋白磷酸化以响应 IGF-1（胰岛素样生长因子 1），PF-4708671 还被发现诱导 S6K1 的 T 环和疏水基序磷酸化，一种依赖于 mTORC1（mTOR 复合体 1）[1] 的效应。 RSK1、RSK2 和 MSK1 是其他被 PF-4708671 抑制的激酶（IC50 分别为 4.7 μM、9.2 μM 和 0.95 μM）。 PF-4708671 降低 HEK-293 细胞中核糖体蛋白 S6 的磷酸化。 PF-4708671 已被用作标准 S6K1 抑制剂，用于研究 S6K1 在多种癌症中的作用。 PF-4708671 与他莫昔芬联用被证明对过度表达 S6K1 [2] 的 ER+ MCF7 细胞非常有效，并通过下调抗凋亡蛋白 Mcl 增强葡萄糖饥饿 MCF7 细胞的细胞死亡-1 和生存 [3]。
PF-4708671 抑制 AKT/mTOR/S6K1 通路导致抑制三阴性 MDA-MB-231 细胞中的细胞迁移并抑制小鼠模型的局部复发[4]。此外，PF-4708671 通过恢复代谢组织中的 Akt S473 磷酸化，改善了高脂喂养肥胖小鼠的葡萄糖耐量[5]。 PF-4708671对NMDA诱导的大鼠视网膜神经毒性具有保护作用[6]。
| Cell experiment [1]: | |
|
Cell lines |
A549 (adenocarcinoma), NCI-H460 (large cell carcinoma), and SK-MES-1 (squamous cell carcinoma) cells |
|
Preparation Method |
Tumor cells were seeded in 96-well plates at a density of 5×103 per well. After incubation in presence of PF-4708671 (0.1µM, 0.3µM, 1µM, 3µM and 10µM) for 24, 48 and 72 hours, respectively, |
|
Reaction Conditions |
0.1µM, 0.3µM, 1µM, 3µM and 10µM for 24, 48 and 72 hours |
|
Applications |
Proliferation abilities of the three NSCLC cell lines were significantly inhibited by PF-4708671. After 24 hours of treatment, PF-4708671 inhibited H460 cell proliferation at 10µM, and A549 and SK-MES-1 cell amounts were significantly reduced at 3µM and 0.1µM, respectively. In addition, H460, A549, and SK-MES-1 cell growth rates were significantly inhibited by PF-4708671 at 0.3µM, 0.1µM, and 0.1µM, respectively, 48 hours post treatment. All cell lines showed significantly reduced proliferation at 72 hour after treatment with 0.1µM PF-4708671. |
| Animal experiment [2]: | |
|
Animal models |
Male C57Bl/6 mice (6 weeks old) |
|
Preparation Method |
Mice were randomly assigned to three groups: (1) control (HF) receiving vehicle (8% EtOH [vol./vol.], 0.2% [wt/vol.] carboxymethylcellulose sterile); (2) treated with PF-4708671 (35 mg kg-1 day-1, i.p.); or (3) treated with rapamycin (2 mg kg-1 day-1, i.p.) for 7 days while being kept on the same high-fat diet. |
|
Dosage form |
Intraperitoneal injection, 35 mg kg-1 day-1 for 7 days. |
|
Applications |
PF-4708671 did not affect body weight or adiposity, 1 week of PF-4708671 treatment was found to improve fasting glucose whereas rapamycin further increased fasting hyperglycaemia in obese mice. |
|
References: [1]: Qiu ZX, Sun RF, Mo XM and Li WM: The p70S6K specific inhibitor PF-4708671 impedes non-small cell lung cancer growth. PLoS One. 11:e01471852016. |
|
| Cas No. | 1255517-76-0 | SDF | |
| 化学名 | 2-[[4-(5-ethylpyrimidin-4-yl)piperazin-1-yl]methyl]-6-(trifluoromethyl)-1H-benzimidazole | ||
| Canonical SMILES | CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F | ||
| 分子式 | C19H21F3N6 | 分子量 | 390.41 |
| 溶解度 | ≥ 19.5mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5614 mL | 12.807 mL | 25.6141 mL |
| 5 mM | 0.5123 mL | 2.5614 mL | 5.1228 mL |
| 10 mM | 0.2561 mL | 1.2807 mL | 2.5614 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet